Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
[Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].
BACKGROUND The aim of this study has been to assess the efficacy and the safety of heparansulphate administered with indobufen in the treatment of occlusive arterial disease . METHODS In a controlled open study , nineteen out- patients with Fontaine 's stage II occlusive arterial disease since one year were r and omly assigned to treatment with indobufen 200 mg/day or indobufen 200 mg/day and heparansulphate 200 mg/day for 6 months . Efficacy assessment s were based on functional evaluations ( pain-free sub-maximal exercise ergometric test , ankle-arm pressure ratio at rest and after induced ischemia ) , on hemocoagulative parameters and on physical signs and subjective symptoms assessed monthly over the whole period of treatment . All patients but one who was lost to follow-up completed the study treatment period as foreseen by the experimental protocol . RESULTS The results of the study show an improvement of 10.89 % ( day 30 ) , 15.92 % ( day 60 ) , 21.04 % ( day 90 ) , 24.19 % ( day 120 ) , 25.18 ( day 150 ) 28.84 % ( day 180 ) end of study in ergometric test pain-free interval obtained by patients treated with heparansulphate and indobufen with respect to patients receiving indobufen alone . Also hemocoagulative parameters and signs and patients ' subjective symptoms were positively influenced by the association heparansulphate and indobufen . CONCLUSIONS On the whole , the results of the study indicate that heparansulphate in association with antiplatelet therapy with indobufen has a beneficial effect in the treatment of peripheral occlusive arterial disease
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .